139 related articles for article (PubMed ID: 17499328)
1. HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3.
Cristillo AD; Lisziewicz J; He L; Lori F; Galmin L; Trocio JN; Unangst T; Whitman L; Hudacik L; Bakare N; Whitney S; Restrepo S; Suschak J; Ferrari MG; Chung HK; Kalyanaraman VS; Markham P; Pal R
Virology; 2007 Sep; 366(1):197-211. PubMed ID: 17499328
[TBL] [Abstract][Full Text] [Related]
2. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.
Pal R; Kalyanaraman VS; Nair BC; Whitney S; Keen T; Hocker L; Hudacik L; Rose N; Mboudjeka I; Shen S; Wu-Chou TH; Montefiori D; Mascola J; Markham P; Lu S
Virology; 2006 May; 348(2):341-53. PubMed ID: 16460776
[TBL] [Abstract][Full Text] [Related]
3. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.
Earl PL; Wyatt LS; Montefiori DC; Bilska M; Woodward R; Markham PD; Malley JD; Vogel TU; Allen TM; Watkins DI; Miller N; Moss B
Virology; 2002 Mar; 294(2):270-81. PubMed ID: 12009868
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine.
Cristillo AD; Wang S; Caskey MS; Unangst T; Hocker L; He L; Hudacik L; Whitney S; Keen T; Chou TH; Shen S; Joshi S; Kalyanaraman VS; Nair B; Markham P; Lu S; Pal R
Virology; 2006 Mar; 346(1):151-68. PubMed ID: 16325880
[TBL] [Abstract][Full Text] [Related]
5. Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine.
Calarota SA; Weiner DB; Lori F; Lisziewicz J
Vaccine; 2007 Apr; 25(16):3070-4. PubMed ID: 17292518
[TBL] [Abstract][Full Text] [Related]
6. Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis.
Hovav AH; Cayabyab MJ; Panas MW; Santra S; Greenland J; Geiben R; Haynes BF; Jacobs WR; Letvin NL
J Virol; 2007 Jan; 81(1):74-83. PubMed ID: 17050608
[TBL] [Abstract][Full Text] [Related]
7. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS.
Gavioli R; Cellini S; Castaldello A; Voltan R; Gallerani E; Gagliardoni F; Fortini C; Cofano EB; Triulzi C; Cafaro A; Srivastava I; Barnett S; Caputo A; Ensoli B
Vaccine; 2008 Jan; 26(5):727-37. PubMed ID: 18096278
[TBL] [Abstract][Full Text] [Related]
8. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.
Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y
Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 Env vaccine comprised of electroporated DNA and protein co-administered with Talabostat.
Cristillo AD; Galmin L; Restrepo S; Hudacik L; Suschak J; Lewis B; Draghia-Akli R; Aziz N; Weiss D; Markham P; Pal R
Biochem Biophys Res Commun; 2008 May; 370(1):22-6. PubMed ID: 18329382
[TBL] [Abstract][Full Text] [Related]
10. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease.
McKenna PM; Koser ML; Carlson KR; Montefiori DC; Letvin NL; Papaneri AB; Pomerantz RJ; Dietzschold B; Silvera P; McGettigan JP; Schnell MJ
J Infect Dis; 2007 Apr; 195(7):980-8. PubMed ID: 17330788
[TBL] [Abstract][Full Text] [Related]
11. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial.
Matano T; Kobayashi M; Igarashi H; Takeda A; Nakamura H; Kano M; Sugimoto C; Mori K; Iida A; Hirata T; Hasegawa M; Yuasa T; Miyazawa M; Takahashi Y; Yasunami M; Kimura A; O'Connor DH; Watkins DI; Nagai Y
J Exp Med; 2004 Jun; 199(12):1709-18. PubMed ID: 15210746
[TBL] [Abstract][Full Text] [Related]
13. Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV.
Zhan X; Martin LN; Slobod KS; Coleclough C; Lockey TD; Brown SA; Stambas J; Bonsignori M; Sealy RE; Blanchard JL; Hurwitz JL
Vaccine; 2005 Nov; 23(46-47):5306-20. PubMed ID: 16095768
[TBL] [Abstract][Full Text] [Related]
14. Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120.
Wang X; Uto T; Akagi T; Akashi M; Baba M
J Virol; 2007 Sep; 81(18):10009-16. PubMed ID: 17609261
[TBL] [Abstract][Full Text] [Related]
15. Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys.
Someya K; Xin KQ; Ami Y; Izumi Y; Mizuguchi H; Ohta S; Yamamoto N; Honda M; Okuda K
Virology; 2007 Oct; 367(2):390-7. PubMed ID: 17628628
[TBL] [Abstract][Full Text] [Related]
16. Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV.
Buckner C; Gines LG; Saunders CJ; Vojtech L; Srivastava I; Gettie A; Bohm R; Blanchard J; Barnett SW; Safrit JT; Stamatatos L
Virology; 2004 Mar; 320(1):167-80. PubMed ID: 15003872
[TBL] [Abstract][Full Text] [Related]
17. DermaVir: a novel topical vaccine for HIV/AIDS.
Lisziewicz J; Trocio J; Whitman L; Varga G; Xu J; Bakare N; Erbacher P; Fox C; Woodward R; Markham P; Arya S; Behr JP; Lori F
J Invest Dermatol; 2005 Jan; 124(1):160-9. PubMed ID: 15654970
[TBL] [Abstract][Full Text] [Related]
18. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic and kinetic analysis of effective simian-human immunodeficiency virus-specific T cell responses in DNA--and fowlpox virus-vaccinated macaques.
Stratov I; Dale CJ; Kent SJ
Virology; 2005 Jul; 337(2):222-34. PubMed ID: 15907968
[TBL] [Abstract][Full Text] [Related]
20. Prime-boost strategies in DNA vaccines.
Dale CJ; Thomson S; De Rose R; Ranasinghe C; Medveczky CJ; Pamungkas J; Boyle DB; Ramshaw IA; Kent SJ
Methods Mol Med; 2006; 127():171-97. PubMed ID: 16988455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
